Effect of Pharmacogenetic Testing for Statin Myopathy Risk vs Usual Care on Blood Cholesterol A Randomized Clinical Trial

Question Can pharmacogenetic results for statin myopathy risk be used clinically without the unintended harms of statin avoidance or underdosing? Findings In this randomized clinical trial including 408 patients, statin-naive patients whose physicians knew their SLCO1B1 genotype results at baseline...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JAMA network open 2020-12, Vol.3 (12), p.e2027092-e2027092, Article 2027092
Hauptverfasser:	Vassy, Jason L., Gaziano, J. Michael, Green, Robert C., Ferguson, Ryan E., Advani, Sanjay, Miller, Stephen J., Chun, Sojeong, Hage, Anthony K., Seo, Soo-Ji, Majahalme, Nilla, MacMullen, Lauren, Zimolzak, Andrew J., Brunette, Charles A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Atherosclerosis Boston Cardiology Cholesterol - blood Cholesterol, LDL - blood Cholesterol, LDL - drug effects Clinical trials Female General & Internal Medicine Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology Intervention Life Sciences & Biomedicine Liver-Specific Organic Anion Transporter 1 - drug effects Liver-Specific Organic Anion Transporter 1 - genetics Male Medication Adherence - statistics & numerical data Medicine, General & Internal Middle Aged Muscular Diseases Online Only Original Investigation Pharmacogenetics - methods Pharmacy and Clinical Pharmacology Primary care Risk Factors Science & Technology Statins United States United States Department of Veterans Affairs
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!